Healthcare, Pharma & Life Sciences

Aria Care Partners Names Dr. Veda Lewis-Simmons Chief Medical Officer of Podiatry

Image
Aria Care Partners Names Dr. Veda Lewis-Simmons Chief Medical Officer of Podiatry

Overland Park, Kan. – September 25, 2026 -- Aria Care Partners has appointed Veda Lewis-Simmons, DPM, MHA, as chief medical officer of podiatry, giving her oversight of operational effectiveness and clinical quality for the company's onsite podiatry services across skilled nursing facilities (SNFs).

Aria Care Partners taps board-certified podiatrist to lead clinical quality for SNF foot care programs

Dr. Lewis-Simmons holds a master's degree in healthcare administration and a Doctor of Podiatric Medicine and Surgery from Des Moines University Medicine and Health Sciences. She completed her residency at the University of Texas Health Science Center in San Antonio and is board certified.

ACROBiosystems Launches CHO-Direct, ACRO AIx for AI Drug Discovery

San Diego – September 25, 2026 -- ACROBiosystems has launched CHO-Direct, a rapid high-throughput affinity validation service that delivers antibody affinity data in as little as four days from sequence submission, alongside a broader infrastructure platform called ACRO AIx aimed at AI-driven drug discovery (AIDD).

CHO-Direct compresses antibody validation timelines to four days

Using an optimized CHO cell system, CHO-Direct converts computationally generated antibody sequences into structured affinity data within days, addressing a bottleneck where AI tools generate candidate sequences faster than labs can validate them. The service leverages the protein-folding and post-translational modification environment of mammalian cells while maintaining compatibility with CHO systems already used in downstream development and manufacturing.

Jiro: CMS Modifier 25 Plan Would Shift $889M, Hit Private Practices

Image
Jiro: CMS Modifier 25 Plan Would Shift $889M, Hit Private Practices

Austin, Texas – September 25, 2026 -- A proposed Medicare payment change involving Modifier 25 would reallocate approximately $889 million in annual fee-for-service payments, with private practices and solo physicians absorbing $724.4 million, or 81.5%, of the modeled reductions, according to a new analysis from Jiro Health.

Six specialties bear 82.3% of the total reduction

Jiro's Practice Impact Analysis, titled "Who Pays for CMS's Modifier 25 Proposal?", found that six medical specialties account for roughly $732 million of the modeled impact. Dermatology alone represents $395.4 million, or 44.5% of the total reallocation. Podiatric medicine and surgery, orthopaedic surgery, otolaryngology, ophthalmology and family medicine together account for an additional $336 million.

RS2 Healthcare Partners Takes Stake in Medtech Manufacturer KMM Group

Image
RS2 Healthcare Partners Takes Stake in Medtech Manufacturer KMM Group

Boston – September 25, 2026 -- RS2 Healthcare Partners has completed an investment in KMM Group, a Hatboro, Pennsylvania-based precision contract manufacturer for the medical device industry, marking the Boston private equity firm's first new platform deal since narrowing its focus exclusively to lower middle-market healthcare investing.

RS2 names industry veteran J. Mark King as KMM's new CEO

J. Mark King, who brings more than 30 years of medical device industry experience, has been appointed President and Chief Executive Officer of KMM. King previously served as President and CEO of Tegra Medical, a medical device contract manufacturer and former RS2 portfolio company, and has also acted as an advisor to KMM prior to the deal.

"I am honored and excited to continue building on KMM's momentum," King said, citing a long working history with RS2's principals.

NFID Survey: Half of US Adults Skip Respiratory Vaccines Despite Broad Support

Image
NFID Survey: Half of US Adults Skip Respiratory Vaccines Despite Broad Support

Washington – September 25, 2026 -- More than half of US adults did not attempt to get a flu, COVID-19, RSV, or pneumococcal vaccine in the past year, even though 77% agree vaccines are among the best proven tools against serious infectious disease, according to a new national survey released by the National Foundation for Infectious Diseases (NFID).

Survey finds 48% of adults tried to get at least one of four respiratory vaccines in the past year

The survey, conducted by NORC at the University of Chicago among 1,206 US adults age 18 and older between August 13-17, 2026, has a margin of sampling error of ±3.6 percentage points. Just 44% tried to get a flu vaccine and only 23% attempted a COVID-19 vaccine, despite 89% of respondents agreeing that anyone who wants vaccine access should have it and 71% saying benefits strongly outweigh risks.

E Tech Group to Address Lab Automation Compliance Gaps at ISPE Show

Image
E Tech Group to Address Lab Automation Compliance Gaps at ISPE Show

West Chester, Ohio – September 25, 2026 -- E Tech Group will present on the compliance and data integrity risks of scaling laboratory automation from pilot to full production at the ISPE Boston Area Chapter 2026 Product Show on October 7 at Gillette Stadium in Foxborough, Massachusetts.

Session targets the gap between pilot success and regulated production failure

Sura Hadi, Director of Laboratory Automation and Industrial Robotics (LAIR) at E Tech Group, will lead the 3:00 p.m. ET session, "From Pilot to Production: Scaling Lab Automation Without Breaking Compliance, Data Integrity, or Teams," in West Red Level, Suite 81. The talk addresses why automation pilots that succeed in contained workflows frequently break down when expanded into regulated manufacturing environments, where instruments must connect to scheduling systems, Laboratory Information Management Systems (LIMS), Electronic Laboratory Notebooks (ELN), and other enterprise platforms.

US Social Connection Survey Finds Persistent Loneliness, Weak Ties

Image
US Social Connection Survey Finds Persistent Loneliness, Weak Ties

Washington – September 25, 2026 -- Four in ten Americans report moderate to severe loneliness, according to the second annual Social Connection in AmericaTM survey, which found that key indicators of social connection weakened for a second consecutive year.

Nearly 70% of Americans see loved ones no more than once or twice a month

The survey, part of a 25-year national tracking initiative led by RAND and The Connection Institute with founding funder the Barnes Family Foundation, found that one in five Americans meet with people they care about only a few times a year or less. Time constraints are the top barrier to connection, cited by 30.6% of respondents, followed by distance (14.8%), effort (13.3%) and social anxiety (11.1%).

Sanyou Bio, NovoCodex Partner to Co-Develop Dual-Payload ADCs

Shanghai – September 25, 2026 -- Sanyou Biopharmaceuticals Co., Ltd. and NovoCodex Biopharmaceuticals Co., Ltd. have signed a strategic collaboration agreement to jointly develop next-generation antibody-drug conjugates (ADCs), combining Sanyou Bio's AI-driven antibody discovery platforms with NovoCodex's clinically validated site-specific conjugation technology.

NovoCodex brings a clinically validated conjugation platform to the partnership

NovoCodex's proprietary NovoCodeTM platform incorporates unnatural amino acids into antibodies to achieve defined, controllable conjugation sites, producing homogeneous ADC products rather than the heterogeneous mixtures typical of traditional random conjugation. The technology has been validated in the pivotal Phase III trial of ARX788 and supported ARX305 in showing a favorable safety window and durable antitumor activity in advanced renal cancer patients with high CD70 expression.

Clarius Repeats on TIME's Top 500 Global HealthTech List

Image
Clarius Repeats on TIME's Top 500 Global HealthTech List

Vancouver – September 25, 2026 -- Clarius Mobile Health has been named to TIME's list of the World's Top HealthTech Companies 2026 for the second consecutive year, placing it among just 500 companies selected from thousands reviewed globally.

TIME and Statista ranked Clarius on financial performance, reputation and online engagement

The list, presented by TIME and Statista Inc., was announced on September 25, 2026. Statista evaluated thousands of HealthTech companies worldwide before narrowing the field to the top 500 recognized for their performance across financial, reputational and engagement metrics.

Aqua Medical Closes Series B to Fund US Trial for Diabetes Device

Image
Aqua Medical Closes Series B to Fund US Trial for Diabetes Device

Pleasanton, Calif. – – September 25, 2026 -- Aqua Medical, Inc. has closed a Series B financing round led by Nashville-based Relevance Ventures, with proceeds earmarked to complete its ongoing U.S. RESTORE-1 pilot study and prepare for a planned U.S. pivotal trial of its investigational diabetes procedure.

Series B capital targets completion of RESTORE-1 pilot and pivotal trial launch

The financing will fund the remaining stages of the RESTORE-1 pilot study, which is evaluating Aqua Medical's Proximal Intestinal Mucosal Ablation (PIMA) procedure for Type 2 diabetes under an FDA-approved Investigational Device Exemption. The company said the round will also support operational preparations, including patient recruitment infrastructure, for a larger planned pivotal trial subject to regulatory authorization.